Refractory immune-mediated and haematological diseases: candidates for peptide receptor radiotherapy?

Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field

“…Van Hagen et al (Vanhagen et al, 1994b) In this respect, the development of the novel SS analogue, SOM-230, is of high interest, as in RA expression of sst 1,2,3 has been demonstrated (Sakane and Suzuki, 1998). Refractory RA might also be a target for radiotherapy (Kwekkeboom et al, 2000), in which radionuclidecoupled SS analogues are injected in synovia of affected joints. Because of the expression of sst, the radiolabeled SS analogue is internalized in the cells and the radioactivity causes cell death of the infiltrating synoviocytes.…”